Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Cell|August 21, 2012
ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalitiesYuan Wang, Edward Kim, Xiaojing Wang, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|January 7, 2012
Treatment of vestibular schwannoma cells with ErbB inhibitorsMatthew L Bush, Sarah S Burns, Janet Oblinger, et al.
Neuro-Oncology Advances|March 13, 2024
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient modelsSrirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, et al.
BMC Cell Biology|January 12, 2008
The role of Drosophila Merlin in spermatogenesisNatalia V Dorogova, Elena M Akhmametyeva, Sergei A Kopyl, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|August 10, 2013
Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolideSamuel A Spear, Sarah S Burns, Janet L Oblinger, et al.
Experimental Neurology|June 15, 2017
Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiationJanet L Oblinger, Sarah S Burns, Jie Huang, et al.
Cancer Research|November 16, 2012
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growthSarah S Burns, Elena M Akhmametyeva, Janet L Oblinger, et al.
European Journal of Cancer (Oxford, England : 1990)|April 11, 2009
Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cellsTina X Lee, Mark D Packer, Jie Huang, et al.
Oncotarget|January 19, 2015
Group I Paks as therapeutic targets in NF2-deficient meningiomaHoi-Yee Chow, Biao Dong, Sergio G Duron, et al.
Scientific Reports|August 20, 2024
Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomasJanet L Oblinger, Jack Wang, Georgia D Wetherell, et al.
Pageof 5